aliskiren effective alone and in combination for hypertension

1
Inpharma 1522 - 28 Jan 2006 Aliskiren effective alone and in combination for hypertension The results of three phase III trials indicate that the oral renin inhibitor aliskiren * [SPP 100] may be an effective and well tolerated treatment for hypertension, both as monotherapy and in combination with certain other antihypertensives. In one trial, aliskiren 150mg administered with amlodipine 5mg provided improved BP control and a decrease in oedema in patients with hypertension. In another trial, involving 837 patients with hypertension and diabetes mellitus, aliskiren monotherapy produced double digit decreases in systolic and diastolic BP; when coadministered with ramipril, aliskiren was associated with significant additional decreases in systolic and diastolic BP. Furthermore, aliskiren produced a reduction in dry cough when administered with the ACE inhibitor. In a third trial, aliskiren monotherapy was reported to have placebo-like tolerability in patients with hypertension treated for > 1 year. * Novartis, Speedel Pharmaceuticals; phase III for hypertension in the US, Europe and Japan Speedel Pharmaceuticals Inc. Novartis New Phase III Data With SPP100 (aliskiren, Rasilez) Reconfirms Strong Efficacy and Excellent Safety Profile as Monotherapy and Co-Administration Therapy for Treatment of Hypertension. Media Release : 19 Jan 2006. Available from: URL: http://www.speedel.com 809059148 1 Inpharma 28 Jan 2006 No. 1522 1173-8324/10/1522-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Post on 12-Dec-2016

214 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Aliskiren effective alone and in combination for hypertension

Inpharma 1522 - 28 Jan 2006

Aliskiren effective alone and incombination for hypertension

The results of three phase III trials indicate that theoral renin inhibitor aliskiren* [SPP 100] may be aneffective and well tolerated treatment for hypertension,both as monotherapy and in combination with certainother antihypertensives.

In one trial, aliskiren 150mg administered withamlodipine 5mg provided improved BP control and adecrease in oedema in patients with hypertension.

In another trial, involving 837 patients withhypertension and diabetes mellitus, aliskirenmonotherapy produced double digit decreases insystolic and diastolic BP; when coadministered withramipril, aliskiren was associated with significantadditional decreases in systolic and diastolic BP.Furthermore, aliskiren produced a reduction in drycough when administered with the ACE inhibitor.

In a third trial, aliskiren monotherapy was reported tohave placebo-like tolerability in patients withhypertension treated for > 1 year.* Novartis, Speedel Pharmaceuticals; phase III for hypertension in theUS, Europe and Japan

Speedel Pharmaceuticals Inc. Novartis New Phase III Data With SPP100 (aliskiren,Rasilez) Reconfirms Strong Efficacy and Excellent Safety Profile as Monotherapyand Co-Administration Therapy for Treatment of Hypertension. Media Release :19 Jan 2006. Available from: URL: http://www.speedel.com 809059148

1

Inpharma 28 Jan 2006 No. 15221173-8324/10/1522-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved